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Objectives In the present substudy of the Hebe trial, we investigated the effect of intracoronary bone
marrow mononuclear cell (BMMC) and peripheral blood mononuclear cell (PBMC) therapy on the recov-
ery of microcirculation in patients with reperfused ST-segment elevation myocardial infarction (STEMI).
Background Several studies have suggested that cell therapy enhances neovascularization after STEMI.
Methods Paired Doppler ﬂow measurements were available for 23 patients in the BMMC group,
18 in the PBMC group, and 19 in the control group. Coronary ﬂow was assessed at 3 to 8 days after
primary percutaneous coronary intervention (PCI) and repeated at 4-month follow-up, with intra-
coronary Doppler ﬂow measurements.
Results At baseline, the coronary ﬂow velocity reserve was reduced in the infarct-related artery and
improved over 4 months in all 3 groups. The increase of coronary ﬂow velocity reserve did not sig-
niﬁcantly differ between the 2 treatment groups and the control group (BMMC group: 2.0  0.5 to
.1  0.7; PBMC group: 2.2  0.6 to 3.2  0.8; control group: 2.0  0.5 to 3.4  0.9). Additionally,
the decrease in hyperemic microvascular resistance index from baseline to 4-month follow-up was
not statistically different between the 2 treatment groups and the control group.
Conclusions In STEMI patients treated with primary PCI in the Hebe trial, adjuvant therapy with BMMCs
or PBMCs does not improve the recovery of microcirculation. Therefore, our data do not support the hy-
pothesis of enhanced neovascularization after this mode of cell therapy. (Multicenter, randomised trial of
intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood
cells after primary percutaneous coronary intervention [PCI]; ISRCTN95796863) (J Am Coll Cardiol
Intv 2011;4:913–20) © 2011 by the American College of Cardiology Foundation
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914In patients with acute ST-segment elevation myocardial
infarction (STEMI), timely restoration of the myocardial
perfusion by advanced revascularization therapies has re-
sulted in increased survival. Although this has been a major
progress in the treatment of STEMI patients, long-term
morbidity remains high. In many patients, the intrinsic
reparative mechanisms fail to prevent further deterioration
of cardiac function after the acute ischemic event, putting
the patient at risk for progression to post-infarct heart
failure. Therefore, augmentation of the healing response is
an appealing concept to improve clinical outcome.
Cell-based therapies have evoked great interest as an
adjuvant therapy in patients with STEMI. Several experi-
mental studies have shown that bone marrow mononuclear
cell (BMMC) therapy enhances neovascularization and
improves functional cardiac outcome after acute myocardial
infarction (1–4). Whereas some of these experimental
studies report that BMMCs stimulate neovascularization in
the peri-infarct zone through in-
corporation into the microvascu-
lature (2,3), other studies sug-
gested paracrine effects (5). In
patients, evidence for this hypoth-
esis is scarce. The large random-
ized REPAIR-AMI (Reinfusion
of Enriched Progenitor Cells and
Infarct Remodeling in Acute
Myocardial Infarction) trial re-
ported a significant improvement
in left ventricular ejection fraction
after BMMC therapy (6). In ad-
dition, an increased recovery of
microcirculation in the infarcted
area was found, supporting the
hypothesis of enhanced neovas-
cularization after this mode of
therapy (7). Other clinical studies investigating BMMC
therapy obtained contradicting results with regard to func-
tional cardiac outcome (8–11). To assess the effect of
BMMC therapy on the recovery of microcirculation, we
examined coronary flow with intracoronary Doppler flow
measurements in STEMI patients that participated in the
Hebe trial. The Hebe trial was a randomized controlled
trial, evaluating the effect of intracoronary BMMC infu-
sion and intracoronary peripheral blood mononuclear cell
(PBMC) infusion on cardiac recovery in patients with
STEMI treated by primary percutaneous coronary inter-
vention (PCI) (12). Although the Hebe trial showed no
beneficial effects of BMMC therapy or PBMC therapy
with regard to functional cardiac outcome measured by
cardiovascular magnetic resonance imaging (CMR) at short-
term follow up (13), cell therapy might have influenced
neovascularization in the infarcted area, resulting in improved
Abbreviations
and Acronyms
BMMC  bone marrow
mononuclear cell
CFVR  coronary flow
velocity reserve
CMR  cardiovascular
magnetic resonance imaging
HMRI  hyperemic
microvascular resistance
index
PBMC  peripheral blood
mononuclear cell
STEMI  ST-segment
elevation myocardial
infarctionrecovery of microcirculation.Methods
Study population and procedures. This pre-specified sub-
study was part of the Hebe trial. The design and main
results of the Hebe trial have been reported previously
(12,13). Briefly, between August 2005 and April 2008, a
total of 200 patients with first STEMI that were successfully
treated with primary PCI were included in this multicenter,
randomized, open trial with blinded evaluation of end-
points. All patients underwent CMR and were randomly
assigned in a 1:1:1 ratio to treatment with intracoronary
infusion of autologous BMMCs, intracoronary infusion of
autologous PBMCs, or standard therapy. The study was
conducted in accordance with the Declaration of Helsinki,
and the study protocol was approved by institutional review
boards of the participating institutes. Patients enrolled in
the Academic Medical Center, University of Amsterdam
and VU University Medical Center (both Amsterdam, the
Netherlands) underwent cardiac catheterization at baseline
to assess intracoronary flow. In patients randomized to
BMMC and PBMC therapy, baseline intracoronary flow
measurements were performed before intracoronary cell
therapy. In the control group, catheterization was per-
formed for intracoronary flow measurements only. For
preparation of the cell suspension, either 60 ml heparin
anticoagulated bone marrow aspirate (BMMC group) or
150 to 200 ml venous heparin anticoagulated blood (PBMC
group) was collected and sent to a single cell processing
laboratory. Mononuclear cells were isolated by density
gradient centrifugation and prepared for intracoronary in-
fusion the same day. The detailed cell processing and cell
characterization protocols have been reported previously
(12,14). At 4-month follow-up, intracoronary flow mea-
surements were repeated to assess the recovery of the
intracoronary flow in the 3 treatment groups (Fig. 1).
Intracoronary Doppler ﬂow measurements and data analysis.
Cardiac catheterization was performed by standard tech-
niques. A bolus of 0.1 mg nitroglycerin was administered
into the coronary circulation to induce vasodilation of the
coronary arteries before intracoronary Doppler flow mea-
surements. To assess coronary flow, a 0.014-inch Doppler-
tipped guidewire (Flowire, Volcano Corporation, Rancho
Cordova, California) was positioned in the infarct-related
artery, distal to the previously implanted stent. After opti-
mization of the Doppler signal, average peak flow velocity
recordings were obtained at baseline and during induction
of maximal hyperemia by an intracoronary bolus of 20 to
40 g adenosine. Doppler flow measurements were re-
peated at least 3 times. Coronary flow was also measured in
a reference artery. The position of the Doppler-tipped
guidewire in the infarct-related artery as well as the refer-
ence artery was angiographically documented. At 4-month
follow-up, the Doppler flow measurements were repeated
and coronary flow was assessed at the same position as
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915during cardiac catheterization at baseline. Flow velocities
were recorded continuously on videotape (FloMap, Jomed,
Rancho Cardova, California) and analyzed by an indepen-
dent investigator. Absolute coronary flow velocity reserve
(CFVR) was determined as the ratio of the hyperemic to
baseline average peak flow velocity. Relative CFVR was
calculated as the absolute CFVR in the infarct-related artery
divided by the absolute CFVR in the reference artery. The
hyperemic microvascular resistance index (HMRI) was
defined as the ratio of mean aortic pressure to the average
peak flow velocity during maximum hyperemia. Patients
Figure 1. Study Flow Diagram
AMC  Academic Medical Center, University of Amsterdam, Amsterdam, the N
PBMC  peripheral blood mononuclear cell; PCI  percutaneous coronary inte
versity Medical Center, Amsterdam, the Netherlands.with 70% stenosis in the infarct-related artery or the neference artery at 4-month follow-up were excluded to
void confounding effects.
Statistical analysis. Data with normal distribution are ex-
ressed as mean  SD, and data with non-normal distri-
ution are given as median value (25th to 75th percentile).
ategorical data are presented as number (%). For categor-
cal variables, a chi-square test was used to test for differ-
nces between groups. For continuous variables, a Student t
est or a 1-way analysis of variance was used to compare data
ith a normal distribution, whereas a nonparametric
ruskal-Wallis test was used to compare data with a
lands; BMMC  bone marrow mononuclear cell; IRA  infarct-related artery;
ion; STEMI  ST-segment elevation myocardial infarction; VUMC  VU Uni-ether
rventon-normal distribution. For the comparison of changes in
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916flow parameters between groups, analysis of covariance was
used, including treatment group as the main factor and each
baseline variable as a covariate. Linear multivariable regres-
sion models were used to further investigate the relation
between cell therapy and the change in CFVR and HMRI
when adjusting for baseline variables. A 2-sided p value
0.05 was considered statistically significant. Statistical
analysis was performed with Statistical Package for Social
Sciences software (SPSS for Windows, version 16.0, SPSS,
Inc., Chicago, Illinois).
Results
Patient demographic and clinical characteristics. Of the 76
atients included in the Academic Medical Center and VU
niversity Medical Center, 16 did not have paired intra-
oronary flow measurements and were excluded from this
nalysis (Fig. 1). Of the 60 patients with paired measure-
ents, 23 were allocated to BMMC therapy, 18 to PBMC
herapy, and 19 patients to no cell therapy (control group).
aseline demographic and clinical characteristics are sum-
arized in Table 1. The mean age in the study group was 55
ears, and 83% were men. Baseline demographic and clinical
haracteristics were comparable across the 3 treatment
roups, except for a lower incidence of hypertension in the
BMC group and a higher incidence of Thrombolysis In
yocardial Infarction flow grade 2 after primary PCI in the
MMC group. No differences were found in baseline demo-
raphic and clinical characteristics between the 16 excluded
atients and the study group (data not shown). Furthermore,
o clinical, electrocardiographic, or enzymatic evidence of
einfarction was observed in any patient between primary PCI
nd the cardiac catheterization at 4-month follow-up.
The effect of BMMC or PBMC therapy on the recovery of
microcirculation. Patients underwent baseline intracoronary
Doppler flow measurements at a median of 6 (4 to 7) days after
primary PCI. In the BMMC and PBMC groups, baseline
intracoronary Doppler flow measurements were performed just
before intracoronary cell infusion. Doppler flow measurements
were repeated at a median of 132 (125 to 138) days after
primary PCI. Coronary flow hemodynamic parameters are
listed in Table 2. In summary, the baseline CFVR in the
infarct-related artery was similar in the 3 groups (2.0  0.5 in
the BMMC group, 2.2 0.6 in the PBMC group, and 2.0
0.5 in the control group) as well as the HMRI (2.0  0.5
m Hg s/cm in the BMMC group, 1.9 0.8 mm Hg s/cm in
he PBMC group, and 1.9  0.5 mm Hg s/cm in the control
roup). At 4-month follow-up, the CFVR in the infarct-
elated artery increased to levels similar to the reference artery
Fig. 2A, Table 2). The increase in CFVR in the infarct-
elated artery was not significantly different between the treat-
ent groups and the control group (1.1  0.7 in the BMMC
roup; 1.0 0.8 in the PBMC group; 1.4 0.9 in the control
roup) (Fig. 2B, Table 2). Furthermore, there was a trendoward a decrease in HMRI from baseline to follow-up in all
groups, which was only borderline significant in the control
roup, with no significant differences in change in HMRI
etween the treatment groups and the control group (2.0 0.5
m Hg s/cm to 1.8 0.6 mm Hg s/cm in the BMMC group;
.9  0.8 mm Hg s/cm to 1.8  0.6 mm Hg s/cm in the
BMC group; 1.9  0.5 mm Hg s/cm to 1.7  0.5
mm Hg s/cm in the control group) (Figs. 2C and 2D, Table
). With regard to the reference artery, the change in coronary
ow from baseline to 4-month follow-up was similar among
he 3 groups (Table 2). Finally, no differences were found in
mprovement in relative CFVR among the 3 groups (0.2 0.2
n the BMMC group, 0.1 0.2 in the PBMC group, and 0.3
0.3 in the control group) (Table 2). After adjustment for
aseline variables, the results of the differences between treat-
ent groups did not change, with regard to the change in
FVR and HMRI.
iscussion
Intracoronary infusion of BMMCs or PBMC did not enhance
the recovery of microcirculation after primary PCI in the
present substudy of the Hebe trial. In accordance with other
studies, the CFVR in the infarct-related artery was depressed
in the early phase after primary PCI and increased to levels
similar to the reference artery at 4 months of follow-up.
Additionally, the increase in CFVR was comparable among
the 3 groups. Also, the decrease in HMRI in the infarct-
related artery was similar in the 3 groups. Taken together, it
seems unlikely that BMMC or PBMC therapy enhanced
post-infarct neovascularization in the Hebe study. This is also
consistent with the CMR data from this trial, showing no
beneficial effect of BMMC or PBMC therapy on global and
regional cardiac function at 4 months of follow-up (13).
Our results are in contrast to data from the Doppler
substudy of the REPAIR-AMI trial (7). Several factors
might be responsible for these discrepant findings. In the
present study, all patients received primary PCI according to
the current guidelines to limit the extent of myocardial
injury and to preserve the integrity of the microvasculature.
Importantly, primary PCI was performed within 6 h after
onset of symptoms in almost all patients, with a median of
3.1 h (2.2 to 4.1 h). In the REPAIR-AMI study, the mean
time from symptom onset to reperfusion therapy was longer
than 6 h, and some patients received fibrinolytic therapy
before PCI (7). In a post hoc analysis of the REGENT
(Myocardial Regeneration by Intracoronary Infusion of
Selected Population of Stem Cells in Acute Myocardial
Infarction) trial, the investigators found that patients with
longer-than-median delay from the pain onset to reperfu-
sion (5 h) were more likely to have significant improvement
(11). Therefore, the potential benefit of intracoronary infu-
sion of BMMCs on the recovery of microcirculation might
have been different in our study.
IMI T
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917Furthermore, there are differences in methodology
with regard to the BMMC processing protocol that
Table 1. Patient Demographic and Clinical Character
Characteristic
BMMC
(n 
Age (yrs) 55.2
Male 19 (83
Body mass index (kg/m2) 26.0
Risk factors for coronary artery disease
Diabetes mellitus 1 (4)
Hypertension 10 (44
Family history of coronary heart disease 13 (57
Hypercholesterolemia 5 (22
Current smoking 10 (44
Angiography and infarct treatment
Symptom onset to balloon (h) 3.0 (2.5
Infarct-related artery
Left anterior descending artery 17 (74
Left circumﬂex artery 2 (9)
Right coronary artery 4 (17
TIMI ﬂow grade after primary PCI
2 4 (17
3 19 (83
Cardiovascular magnetic resonance imaging
LV ejection fraction (%) 44.1
LV end-diastolic volume (ml/m2) 94.4
LV end-systolic volume (ml/m2) 53.3
Infarct mass (g/m2) 14.5
Presence of microvascular obstruction 15 (65
Cell infusion
Days after primary PCI 6 (4–
Number of injected cells (106) 291
Absolute number of CD34 cells (106) 6.8
Absolute number of CD14 cells (106) 17.9
Medication at discharge
Aspirin 23 (10
Clopidogrel 23 (10
Beta-blockers 22 (96
ACE inhibitor 22 (96
ATII-receptor blocker 0 (0)
Nitrates 0 (0)
Calcium-channel antagonists 0 (0)
Medication at 4-month follow-up
Aspirin 23 (10
Clopidogrel 18 (78
Beta-blockers 19 (83
ACE inhibitor 20 (87
ATII-receptor blocker 2 (9)
Nitrates 1 (4)
Calcium-channel antagonists 0 (0)
Values are mean SD, n (%), or median (25th to 75th percentile).
ACE  angiotensin-converting-enzyme; AT  angiotensin; BMMC
blood mononuclear cell; PCI percutaneous coronary intervention; Tmight affect the therapeutic potential of the BMMCs.This issue has been extensively addressed by van Beem et al.
(14), who compared the cell processing protocol as applied in
PBMC Group
(n  18)
Control Group
(n  19) p Value
54.6 11.0 54.2 7.4 0.94
14 (78) 17 (90) 0.63
26.3 4.3 26.4 2.4 0.92
0 (0) 0 (0) 0.44
0 (0) 8 (42) 0.004
6 (33) 10 (53) 0.30
2 (11) 3 (16) 0.66
11 (61) 11 (58) 0.47
3.5 (2.1–4.9) 3.0 (2.1–3.9) 0.71
0.28
10 (56) 16 (84)
1 (6) 1 (5)
7 (39) 2 (11)
0.03
0 (0) 0 (0)
18 (100) 19 (100)
42.9 7.9 41.3 8.5 0.62
95.3 13.0 100.4 17.0 0.40
54.7 12.0 59.3 14.8 0.38
10.9 4.6 14.1 7.4 0.22
11 (61) 13 (68) 0.60
5 (4–7) —
288 91 —
0.3 0.1 —
63.5 30.1 —
18 (100) 19 (100) —
18 (100) 19 (100) —
18 (100) 19 (100) 0.44
14 (78) 18 (95) 0.12
1 (6) 1 (5) 0.53
0 (0) 0 (0) —
1 (6) 1 (5) 0.53
18 (100) 18 (95) 0.33
16 (89) 18 (95) 0.28
17 (94) 19 (100) 0.11
13 (72) 18 (95) 0.15
1 (6) 2 (11) 0.86
0 (0) 2 (11) 0.34
0 (0) 1 (5) 0.53
marrow mononuclear cell; LV  left ventricular; PBMC  peripheral
hrombolysis In Myocardial Infarction.istics
Group
23)
8.8
)
3.4
)
)
)
)
–4.1)
)
)
)
)
9.7
13.5
13.6
7.4
)
7)
173
5.1
9.4
0)
0)
)
)
0)
)
)
)
 bonethe Hebe trial with the protocol of the REPAIR-AMI trial. It
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918was concluded that the quantity and quality of the BMMCs
was comparable in terms of BMMC recovery, migration, and
clonogenic capacity. In the Hebe trial, no overnight storage of
cells was included in the protocol, as applied in the REPAIR-
AMI trial. Moreover, there might be small differences in cell
handling between the 2 studies. Therefore, functional differ-
ences that are related to the preparation of cells cannot formally
be excluded.
In the REPAIR-AMI study, Doppler flow measure-
ments showed increased recovery of the CFVR in the
infarct-related artery in patients treated with BMMCs,
compared with the placebo group (7). Of relevance, the
recovery of the CFVR in the placebo group of the
REPAIR-AMI study (1.9  0.5 months to 2.8  1.0 at
4 months) was relatively low as compared with the
control group of the present study (2.0  0.5 months to
3.4  0.9 at 4 months). Also, the study of Bax et al.
(15)—investigating the natural course of coronary flow after
primary PCI—reported a higher increase in CFVR (1.9 0.5
t 1 week to 3.0  0.8 at 6 months) as compared with the
EPAIR-AMI study. It remains unclear whether the
ncreased recovery of the CFVR in the BMMC group in
he REPAIR-AMI study is the result of enhanced
icrovascular repair in the BMMC group or, alterna-
ively, blunted repair in the placebo group.
Study limitations. First of all, our sample size might be
too small to detect small differences in coronary flow
parameters between groups. This study would have,
Table 2. Effect of BMMC and PBMC Therapy on Coronary Flow
BMMC Group (n  23) PBMC G
Baseline Follow-Up Change Baseline Fol
Heart rate (beats/min) 75 14 63 15 13 11 69 10 6
Systolic BP (mm Hg) 112 23 120 18 8 19 110 24 12
Diastolic BP (mm Hg) 68 10 69 8 1 12 66 9 6
Infarct-related artery
Baseline APV (cm/s) 23 10 17 7 6 10 22 11 1
Hyperemic APV (cm/s) 42 13 51 19 8 22 46 19 5
CFVR 2.0 0.5 3.1 0.7 1.1 0.7 2.2 0.6 3.
BMRI (mm Hg s/cm) 4.1 1.6 5.8 2.3 1.7 2.4 4.2 1.8 6.
HMRI (mm Hg s/cm) 2.0 0.5 1.8 0.6 0.2 0.8 1.9 0.8 1.
Reference vessel
Baseline APV (cm/s) 20 6 16 5 4 7 19 8 1
Hyperemic APV (cm/s) 50 13 50 16 1 16 53 22 5
CFVR 2.6 0.6 3.2 0.6 0.5 0.6 2.8 0.5 3.
BMRI (mm Hg s/cm) 4.6 1.7 5.7 1.9 1.1 2.1 4.7 1.6 5.
HMRI (mm Hg s/cm) 1.7 0.6 1.7 0.5 0.0 0.5 1.7 0.6 1.
Relative CFVR 0.8 0.2 1.0 0.3 0.2 0.2 0.8 0.2 0.
Values are mean SD. *p values were determined by analysis of covariance.
APV averagepeak flowvelocity; BMMCbonemarrowmononuclear cell; BMRIbaselinemicr
microvascular resistance index; PBMC peripheral blood mononuclear cell.considering the number of included patients, 80% powerto pick up a mean difference of 0.6 in change of CFVR
between the BMMC group and control group and a
difference of 0.5 mm Hg s/cm in change of HMRI
(assuming a 2-sided alpha of 0.05). Therefore, the
present study was sufficiently powered to detect the
difference in intracoronary Doppler flow measurements as
reported in the REPAIR-AMI substudy (7). Second,
intracoronary pressure measurements were not performed
in this study. Combined Doppler flow and pressure
measurements might provide more accurate information
about changes in microvascular resistance (16). To min-
imize confounding effects of epicardial resistance, patients
with 70% stenosis in the infarct-related artery were
excluded. Third, baseline and follow-up intracoronary
Doppler measurements were not performed on a fixed time
point after primary PCI, which might have influenced the
results. However, no differences in time between primary
PCI and intracoronary Doppler measurements were ob-
served among the 3 groups. Fourth, intracoronary Doppler
measurements were performed only once at 4-month
follow-up. Therefore, potential early or late effects on the
coronary flow have not been evaluated.
Conclusions
In STEMI patients treated with primary PCI, adjuvant therapy
with BMMCs or PBMCs does not improve the recovery of
microcirculation. Therefore, our data do not support the hypoth-
n  18) Control Group (n  19) p Value of Change
Change Baseline Follow-Up Change
BMMS vs.
Control*
PBMS vs.
Control*
3 10 73 7 63 8 10 7 0.49 0.046
9 16 111 17 125 22 15 22 0.25 0.37
3 11 70 7 74 11 5 12 0.09 0.30
5 7 24 10 17 8 7 5 0.70 0.23
6 20 45 16 53 14 8 13 0.77 0.72
1.0 0.8 2.0 0.5 3.4 0.9 1.4 0.8 0.20 0.21
1.8 2.2 3.9 1.2 6.2 2.1 2.3 1.4 0.39 0.36
0.1 0.8 1.9 0.5 1.7 0.5 0.2 0.4 0.73 0.54
3 6 18 6 18 6 0 9 0.23 0.28
1 20 47 10 61 22 14 24 0.06 0.16
0.7 0.7 2.8 0.5 3.4 0.7 0.7 0.6 0.39 0.74
1.2 2.3 5.1 1.4 5.5 1.7 0.3 1.8 0.41 0.34
0.1 0.6 1.8 0.4 1.5 0.5 0.3 0.4 0.07 0.49
0.1 0.2 0.7 0.2 1.0 0.3 0.3 0.3 0.70 0.19
lar resistance index; BPbloodpressure; CFVR coronary flowvelocity reserve; HMRIhyperemicroup (
low-Up
6 9
0 23
9 11
8 13
2 26
2 0.8
1 2.8
8 0.6
6 7
4 14
5 0.8
9 2.2
6 0.4
9 0.2
ovascuesis of enhanced neovascularization after this mode of therapy.
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